<DOC>
	<DOCNO>NCT02542293</DOCNO>
	<brief_summary>This randomize , open-label , multi-center , global , Phase III study determine efficacy safety durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy first-line treatment patient epidermal growth factor receptor ( EGFR ) anaplastic lymphoma kinase ( ALK ) wild-type advanced metastatic NSCLC .</brief_summary>
	<brief_title>Study 1st Line Therapy Study Durvalumab With Tremelimumab Versus SoC Non Small-Cell Lung Cancer ( NSCLC ) ( NEPTUNE ) .</brief_title>
	<detailed_description>Patients randomize 1:1 receive treatment durvalumab + tremelimumab combination therapy SoC therapy . The primary objective study assess efficacy combination treatment compare SoC term Overall Survival ( OS ) patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For inclusion study , patient fulfill follow criterion : Aged least 18 year Documented evidence Stage IV NSCLC No activate EGFR mutation ALK rearrangement No prior chemotherapy systemic therapy recurrent/metastatic NSCLC World Health Organization ( WHO ) Performance Status 0 1 No Prior exposure IMT , include , limited , antiCTLA4 , antiPD1 , anti PDL1 , antiPDL2 antibody , exclude therapeutic anticancer vaccine Patients enter study follow exclusion criterion fulfil : Mixed small cell lung cancer NSCLC histology , sarcomatoid variant Brain metastases spinal cord compression unless patient stable ( asymptomatic ; evidence new emerge brain metastasis ) steroid least 14 day prior start study treatment . Active prior document inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PDL1</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>OS</keyword>
</DOC>